Payment overview · 2025
General Payments
$1,401.44
36 reported records · 11 companies
Healthcare provider profile · identity verified
Tracey Putz, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · COLORADO SPRINGS, CO · NPI 1114518693
Verified facts
What the public records show
CMS Open Payments records show Tracey Putz, FNP-BC received $1,401.44 in general payments during 2025 across 36 reported records.
Medtronic, Inc. accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$487.15 | 34.8% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $373.61 | 26.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $131.80 | 9.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.10 | 8.6% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $108.35 | 7.7% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $85.72 | 6.1% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.80 | 1.7% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $21.46 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.71 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.28 | 1.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.46 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,401.44 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $487.15 | 10 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $228.46 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.10 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $112.86 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $85.72 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $82.93 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $26.15 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $26.15 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $11.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 160 | 46 |
| Montelukast Sodium | Montelukast Sodium | 94 | 20 |
| Metformin Hcl | Metformin Hcl | 91 | 20 |
| Losartan Potassium | Losartan Potassium | 90 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 89 | 29 |
| Omeprazole | Omeprazole | 89 | 27 |
| Trulicity | Dulaglutide | 85 | 15 |
| Lisinopril | Lisinopril | 82 | 26 |
| Prednisone | Prednisone | 81 | 33 |
| Gabapentin | Gabapentin | 80 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 24 |
| Potassium Chloride | Potassium Chloride | 73 | 21 |
| Furosemide | Furosemide | 66 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 21 |
| Jardiance | Empagliflozin | 63 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 20 |
| Sertraline Hcl | Sertraline Hcl | 51 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 11 |
| Famotidine | Famotidine | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 17 |
| Carvedilol | Carvedilol | 39 | 12 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 17 |
| Linzess | Linaclotide | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 17 |
| Levofloxacin | Levofloxacin | 26 | 15 |
| Ozempic | Semaglutide | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Budesonide Dr | Budesonide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,401.44 · 36 records | Medtronic, Inc. | FFRct, General - Pain Management, Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care, KRYSTEXXA, Kerendia, MINIMED 780G, OTEZLA, PURIFIED CORTROPHIN GEL, REPATHA, TEZSPIRE, TWIIST, UPLIZNA, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error